Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study

SeiichiroOzono; TaijiTsukamoto; SeijiNaitoYasuoOhashiTakeshiUedaTsutomuNishiyamaHidekiMaedaHidehitoKusuokaRioAkazawaMototsuguItoHideyukiAkaza

首页> 外文期刊>Japanese journal of clinical oncology. >Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study

【24h】

Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study

机译：Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

The 3-month dosing regimen of degarelix with maintenance doses of 360 and 480 mg was effective and safe for the treatment of Japanese patients with prostate cancer.

著录项

来源
《Japanese journal of clinical oncology.》 |2017年第5期|438-446|共9页
作者
SeiichiroOzono; TaijiTsukamoto; SeijiNaitoYasuoOhashiTakeshiUedaTsutomuNishiyamaHidekiMaedaHidehitoKusuokaRioAkazawaMototsuguItoHideyukiAkaza;
展开▼
作者单位

Hamamatsu University School of Medicine;

Sapporo Medical University;

Chuo UniversityNiigata University Medical and Dental HospitalThe University of Tokyo;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类肿瘤学;
关键词
clinical trial; gonadotropin-releasing hormone antagonist; degarelix; Japan; prostate cancer;

Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study

摘要

著录项

相关主题

期刊订阅